{"protocolSection": {"identificationModule": {"nctId": "NCT01381900", "orgStudyIdInfo": {"id": "CR018541"}, "secondaryIdInfos": [{"id": "28431754DIA3014", "type": "OTHER", "domain": "Janssen Research & Development, LLC"}], "organization": {"fullName": "Janssen Research & Development, LLC", "class": "INDUSTRY"}, "briefTitle": "A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2012-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-06-23", "studyFirstSubmitQcDate": "2011-06-24", "studyFirstPostDateStruct": {"date": "2011-06-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-11-21", "resultsFirstSubmitQcDate": "2013-11-21", "resultsFirstPostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-04-23", "lastUpdatePostDateStruct": {"date": "2014-05-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Janssen Research & Development, LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the safety, tolerability, and efficacy of the addition of canagliflozin relative to the addition of placebo in patients with inadequate glycemic control on metformin alone or in combination with a sulphonylurea.", "detailedDescription": "This is a double-blind (neither study staff or the patient will know the identity of the treatment assigned) study of canagliflozin where Chinese and other Asian adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control on metformin alone or in combination with a sulphonylurea (SU) will be randomized (assigned to 1 of 3 treatments by chance) to receive the addition of treatment with canagliflozin 100 mg once daily, canagliflozin 300 mg once daily, or matching placebo capsules (placebo is a treatment identical in appearance to canagliflozin but does not contain active drug). All patients will take orally (by mouth) 1 single-blind placebo capsule once daily before the first meal of the day for up to 2 weeks (last dose of single-blind placebo to be taken the day before the baseline (Day 1) visit. On Day 1, patients will take orally, once daily 1 capsule of canagliflozin 100 mg, canagliflozin 300 mg, or placebo before the first meal of the day for up to 18 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Canagliflozin", "Placebo", "Type 2 diabetes mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 678, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Canagliflozin 100mg", "type": "EXPERIMENTAL", "description": "Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "interventionNames": ["Drug: Canagliflozin 100mg", "Drug: Metformin", "Drug: Sulphonylurea"]}, {"label": "Canagliflozin 300mg", "type": "EXPERIMENTAL", "description": "Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "interventionNames": ["Drug: Canagliflozin 300mg", "Drug: Metformin", "Drug: Sulphonylurea"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "interventionNames": ["Drug: Placebo", "Drug: Metformin", "Drug: Sulphonylurea"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Canagliflozin 100mg", "description": "Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).", "armGroupLabels": ["Canagliflozin 100mg"]}, {"type": "DRUG", "name": "Canagliflozin 300mg", "description": "Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).", "armGroupLabels": ["Canagliflozin 300mg"]}, {"type": "DRUG", "name": "Metformin", "description": "The participant's stable dose of background therapy of metformin should be continued throughout the study.", "armGroupLabels": ["Canagliflozin 100mg", "Canagliflozin 300mg", "Placebo"]}, {"type": "DRUG", "name": "Sulphonylurea", "description": "The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.", "armGroupLabels": ["Canagliflozin 100mg", "Canagliflozin 300mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean change in HbA1c from baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 18"}], "secondaryOutcomes": [{"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 18"}, {"measure": "Percent Change in Body Weight From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "timeFrame": "Day 1 (Baseline) and Week 18"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <7% at Week 18", "description": "The table below shows the percentage of patients with HbA1c \\<7% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "timeFrame": "Day 1 (Baseline) and Week 18"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18", "description": "The table below shows the percentage of patients with HbA1c \\<6.5% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "timeFrame": "Day 1 (Baseline) and Week 18"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with T2DM with inadequate glycemic control on metformin monotherapy or on metformin in combination with an SU at protocol-specified doses and having HbA1c \\>=7.0% and \\<=10.5% at Week -2 are eligible for enrollment in the study.\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements \\>=270 mg/dL (15 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling\n* History of a severe hypoglycemic episode within 6 months before screening\n* History of or current illness considered to be clinically significant by the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Janssen Research & Development, LLC Clinical Trial", "affiliation": "Janssen Research & Development, LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Baotou", "country": "China", "geoPoint": {"lat": 40.65222, "lon": 109.82222}}, {"city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"city": "Changchun", "country": "China", "geoPoint": {"lat": 43.88, "lon": 125.32278}}, {"city": "Changsha", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"city": "Chengdu", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"city": "Chongqing", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"city": "Guangzhou", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"city": "Hangzhou", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"city": "Harbin", "country": "China", "geoPoint": {"lat": 45.75, "lon": 126.65}}, {"city": "Nanchang", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"city": "Nanjing", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"city": "Nanning", "country": "China", "geoPoint": {"lat": 22.81667, "lon": 108.31667}}, {"city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"city": "Shenyang", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"city": "Shiyan", "country": "China", "geoPoint": {"lat": 32.6475, "lon": 110.77806}}, {"city": "Siping", "country": "China", "geoPoint": {"lat": 43.16143, "lon": 124.37785}}, {"city": "Su Zhou", "country": "China"}, {"city": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"city": "Wuxi", "country": "China", "geoPoint": {"lat": 31.56887, "lon": 120.28857}}, {"city": "Xi'An", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"city": "Kota Bharu", "country": "Malaysia", "geoPoint": {"lat": 6.13328, "lon": 102.2386}}, {"city": "Pulau Pinang", "country": "Malaysia", "geoPoint": {"lat": 3.55, "lon": 102.56667}}, {"city": "Selangor", "country": "Malaysia"}, {"city": "Hanoi", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"city": "Ho Chi Minh", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study had two background treatment strata: 331 participants in the metformin alone stratum and 347 in the metformin plus SU. In total, 678 participants were randomly allocated to the 3 treatment arms, 676 received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set and the safety analysis set.", "recruitmentDetails": "This study evaluated the efficacy and safety of canagliflozin in Asian participants with type 2 diabetes mellitus who had inadequate glycemic control on a maximally effective or tolerated dose of metformin alone or metformin plus sulphonylurea (SU). It was conducted between 30 June 2011 and 21 December 2012 and recruited patients from 36 sites.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "FG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "FG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "226"}, {"groupId": "FG001", "numSubjects": "223"}, {"groupId": "FG002", "numSubjects": "227"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "217"}, {"groupId": "FG001", "numSubjects": "214"}, {"groupId": "FG002", "numSubjects": "215"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Subject meets glycemic withdrawal crit.", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Noncompliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Early withdraw", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "BG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "BG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "226"}, {"groupId": "BG001", "value": "223"}, {"groupId": "BG002", "value": "227"}, {"groupId": "BG003", "value": "676"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "184"}, {"groupId": "BG001", "value": "187"}, {"groupId": "BG002", "value": "186"}, {"groupId": "BG003", "value": "557"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "41"}, {"groupId": "BG003", "value": "119"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.8", "spread": "9.35"}, {"groupId": "BG001", "value": "56.5", "spread": "8.25"}, {"groupId": "BG002", "value": "56.4", "spread": "9.21"}, {"groupId": "BG003", "value": "56.3", "spread": "8.94"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "101"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "114"}, {"groupId": "BG003", "value": "314"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "125"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "113"}, {"groupId": "BG003", "value": "362"}]}]}]}, {"title": "Region Enroll", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "China", "categories": [{"measurements": [{"groupId": "BG000", "value": "213"}, {"groupId": "BG001", "value": "210"}, {"groupId": "BG002", "value": "213"}, {"groupId": "BG003", "value": "636"}]}]}, {"title": "Malaysia", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "12"}]}]}, {"title": "Vietnam", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean change in HbA1c from baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of double-blind study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Day 1 (Baseline) and Week 18", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "223"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.096"}, {"groupId": "OG001", "value": "-0.97", "spread": "0.095"}, {"groupId": "OG002", "value": "-1.06", "spread": "0.095"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.644", "ciUpperLimit": "-0.367", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.071"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.731", "ciUpperLimit": "-0.453", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.071"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Day 1 (Baseline) and Week 18", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "223"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "0.237"}, {"groupId": "OG001", "value": "-1.44", "spread": "0.236"}, {"groupId": "OG002", "value": "-1.83", "spread": "0.235"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-1.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.375", "ciUpperLimit": "-0.694", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.173"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-1.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.769", "ciUpperLimit": "-1.089", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.173"}]}, {"type": "SECONDARY", "title": "Percent Change in Body Weight From Baseline to Week 18", "description": "The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "populationDescription": "Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Pecent change", "timeFrame": "Day 1 (Baseline) and Week 18", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "223"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "0.4"}, {"groupId": "OG001", "value": "-2.9", "spread": "0.4"}, {"groupId": "OG002", "value": "-3.1", "spread": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-2.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.7", "ciUpperLimit": "-1.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.9", "ciUpperLimit": "-1.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <7% at Week 18", "description": "The table below shows the percentage of patients with HbA1c \\<7% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "populationDescription": "Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Day 1 (Baseline) and Week 18", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "223"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.8"}, {"groupId": "OG001", "value": "49.1"}, {"groupId": "OG002", "value": "52.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.09", "ciUpperLimit": "5.09"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.55", "ciUpperLimit": "6.27"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18", "description": "The table below shows the percentage of patients with HbA1c \\<6.5% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "populationDescription": "Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Day 1 (Baseline) and Week 18", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "223"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.7"}, {"groupId": "OG001", "value": "21.6"}, {"groupId": "OG002", "value": "25.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.45", "ciUpperLimit": "4.48"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.88", "ciUpperLimit": "5.75"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse event data were collected for the duration of the study, consisting of an 18-week double-blind treatment phase and a 4-week follow-up period.", "description": "The total number of adverse events listed in the \"Other (non-Serious) Adverse Events\" table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any of the treatment arms during the study.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "seriousNumAffected": 4, "seriousNumAtRisk": 226, "otherNumAffected": 22, "otherNumAtRisk": 226}, {"id": "EG001", "title": "Canagliflozin 100 mg", "description": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "seriousNumAffected": 5, "seriousNumAtRisk": 223, "otherNumAffected": 27, "otherNumAtRisk": 223}, {"id": "EG002", "title": "Canagliflozin 300 mg", "description": "Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.", "seriousNumAffected": 4, "seriousNumAtRisk": 227, "otherNumAffected": 27, "otherNumAtRisk": 227}], "seriousEvents": [{"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 227}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 227}]}, {"term": "Lung infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 227}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 227}]}, {"term": "Tracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 227}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Neuritis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 227}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 227}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 226}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 223}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 227}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Vice President, Franchise Medical Leader, Cardiovascular & Metabolism Franchise", "organization": "Janssen Research & Development, LLC", "phone": "1-800-526-7736"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068896", "term": "Canagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}